A liquid reagent drop-in of CD23-ECD in the DURAClone RE CLB panel could further confirm B-cell CLL and discern B-cell CLL from other CD19/CD5 co-expressing target populations.17,18,33. This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.